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ABSTRACT 
 
 
Artificial Intelligence is set to revolutionize multiple fields in the coming years. One subset of 
AI, machine learning, shows immense potential for application in a diverse set of medical 
specialties, including diagnostic pathology. In this study, we investigate the utility of the Apple 
Create ML and Google Cloud Auto ML, two machine learning platforms, in a variety of 
pathological scenarios involving lung and colon pathology. First, we evaluate the ability of the 
platforms to differentiate normal lung tissue from cancerous lung tissue. Also, the ability to 
accurately distinguish two subtypes of lung cancer (adenocarcinoma and squamous cell 
carcinoma) is examined and compared. Similarly, the ability of the two programs to differentiate 
colon adenocarcinoma from normal colon is assessed as is done with lung tissue. Also, cases of 
colon adenocarcinoma are evaluated for the presence or absence of a specific gene mutation 
known as KRAS. Finally, our last experiment examines the ability of the Apple and Google 
platforms to differentiate between adenocarcinomas of lung origin versus colon origin. In our 
trained models for lung and colon cancer diagnosis, both Apple and Google machine learning 
algorithms performed very well individually and with no statistically significant differences 
found between the two platforms. However, some critical factors set them apart. Apple Create 
ML can be used on local computers but is limited to an Apple ecosystem. Google Auto ML is 
not platform specific but runs only in Google Cloud with associated computational fees. In the 
end, both are excellent machine learning tools that have great potential in the field of diagnostic 
pathology, and which one to choose would depend on personal preference, programming 
experience, and available storage space. 
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1. INTRODUCTION 
 
Artificial intelligence (AI), first described in 1956, describes a field of computer science in 
which machines are trained to learn from experience. The term was popularized by the 1956 
Dartmouth College Summer Research Project on Artificial Intelligence[1]. The field of AI is 
rapidly growing and has the potential to affect many aspects of our lives. The recent 
announcement from the White House by President Trump to launch the American AI initiative, 
allocating resources and funding for AI development, demonstrates this[2]. This initiative has a 
goal to not only improve American’s quality of life but also to maintain national security and 
economic prosperity. As further research and development are conducted under this initiative, it 
is anticipated that rapid breakthroughs in AI technology will have a dramatic impact in multiple 
areas of society. 
 
Machine learning, a subset of AI, was defined in 1959 by Arthur Samuel and is achieved by 
employing mathematical models to compute sample data sets[3]. Originating from statistical 
linear models, neural networks were conceived to accomplish these tasks[4]. These pioneering 
scientific achievements led to recent developments of deep neural networks. These models are 
created to recognize patterns and achieve computational excellence within a matter of minutes, 
often far exceeding human ability[5]. They can lead to increased efficiency by improved 
turnaround time due to decreased computation time, and high precision and recall[6]. 
 
Machine learning has the potential for numerous applications in the health care field[7][8][9]. 
One promising application is in the field of anatomic pathology, where specimens surgically 
removed from the patient are examined microscopically by Pathologists to render a diagnosis. 
Machine learning allows representative images to be used to train the computer to recognize 
patterns from labeled photographs. Based on a set of images selected to represent a specific 
tissue or disease process, the computer has the potential to be trained to evaluate and recognize 
imported images from patients, and render a diagnosis[10]. Prior to modern machine learning 
models, users would have to import many thousands of training images to produce algorithms 
that could recognize patterns with high accuracy. Modern machine learning algorithms allow for 
a model known as transfer learning, such that far fewer images are required for training[11]–
[13]. 
 
Two novel machine learning platforms available for public use are offered through Google[14] 
and Apple[15]. They offer a user-friendly interface with minimal experience in computer 
science. Google AutoML is a beta release that utilizes machine learning via Cloud services to 
store and retrieve data with ease. No coding knowledge is required. Apple’s machine learning 
platform, Apple Create ML Module, provides computer-based machine learning, requiring only a 
few lines of code to be operational.  
 
We have previously reported using machine learning via the Apple Create ML Module in 
detecting non-small cell lung cancers (adenocarcinomas and squamous cell carcinomas) and 
colon cancers with very high accuracy[16][17]. In the present study, we expand on these findings 
by comparing the Apple platform to Google’s AutoML platform. Using limited training data, 
both programs are compared for precision and recall in differentiating a variety of surgical 
pathology diagnoses. The lungs and colon are among the most common sites for cancers in 
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America and are the top two causes of cancer-related deaths[18]. The vast majority of colon 
cancers are a type known as adenocarcinoma. Lung cancers commonly are classified into several 
subtypes based on morphologic and other characteristics. Among these, adenocarcinoma and 
squamous cell carcinoma, both in a group known as non-small cell carcinoma, represent the two 
most common types of lung cancer.  
 
In this study, we investigate the utility of the two machine learning platforms to a variety of 
pathologic scenarios involving lung and colon pathology. First, we evaluate the ability of the 
platforms to differentiate normal lung tissue from cancerous lung tissue. Also, the ability to 
accurately distinguish two subtypes of lung cancer (adenocarcinoma and squamous cell 
carcinoma) is examined and compared. 
 
Similarly, the ability of the two programs to differentiate colon adenocarcinoma from the normal 
colon is assessed as is done with lung tissue. In addition, cases of colon adenocarcinoma are 
assessed for the presence or absence of a specific gene mutation known as KRAS. KRAS is a 
proto-oncogene found in a variety of cancers, including approximately 40% of colon 
adenocarcinomas[19]. For colon cancers, the presence or absence of the KRAS mutation has 
important implications for patients as it determines whether the tumor will respond to specific 
chemotherapy agents[20]. The presence of the KRAS gene is currently determined by complex 
molecular testing of tumor tissue[21]. However, we assess the potential of machine learning to 
determine if the mutation is present by computerized morphologic analysis alone.  
 
Finally, our last experiment examines the ability of the Apple and Google platforms to 
differentiate between adenocarcinomas of lung origin versus colon origin. Such information may 
be useful in determining the site of origin in tumors that have spread to other parts of the 
body[22]. 
 
 
2. MATERIALS AND METHODS 
 
2.1 Image acquisition  
 
Fifty cases of lung squamous cell carcinoma, fifty cases of lung adenocarcinoma, and fifty cases 
of colon adenocarcinoma were retrieved from our molecular database. 25 colon adenocarcinoma 
cases were positive for KRAS mutation, while 25 cases were negative for KRAS mutation. 750 
total images of lung tissue (250 benign lung tissue, 250 lung adenocarcinomas, and 250 lung 
squamous cell carcinomas) and 500 total images of colon tissue (250 benign colon tissue and 250 
colon adenocarcinoma) were obtained using a Leica Microscope MC190 HD Camera (Leica 
Microsystems, Wetzlar, Germany) connected to an Olympus BX41 microscope (Olympus 
Corporation of the Americas, Center Valley, PA, USA) and the Leica Acquire 9072 software for 
Apple computers. All the images were captured at a resolution of 1024 x 768 pixels using a 60x 
dry objective.   Lung tissue images were captured and saved on a 2012 Apple MacBook Pro 
computer, and colon images were captured and saved on a 2011 Apple iMac computer. Both 
computers were running macOS v10.13 (Apple Inc, Cupertino, CA, USA). The Leica Acquire 
9072 software works on macOS v10.13 but not on the latest macOS v10.14. 
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2.2 Creating Image Classifier Models using Apple Create ML  
 
Apple Create ML is a suite of machine learning products that use tools such as the Swift 
programming language and the macOS playground to create and train custom machine learning 
models on mac computers[15]. The suite contains many features including Image Classification 
to train a machine learning model to classify images, Natural Language Processing to classify 
natural language text, and Tabular Data to train models that deal with labeling information or 
estimating new quantities. We used Create ML Image Classification to create Image Classifier 
Models for our project. 
For each model, we followed the following procedure. We open the Apple Xcode macOS 
Playground v10 on a 2018 Apple MacBook Pro (macOS v10.14, 2.3 GHz Intel Core I5, 8 GB 
2133 MHz LPDDR3, Intel Iris Plus Graphics 655 1536 MB, 256 SSD) to create Image Classifier 
Model with following lines of swift code: 
import CreateMLUI 
let builder = MLImageClassifierBuilder() 
builder.showInLiveView() 
We then opened the assistant editor in Xcode and ran the code. The live view displayed the 
image classifier UI. We then dragged in the training folder for training and validating the model. 
Once training and validation were complete, we dragged in the testing folder to evaluate the 
model performance on the indicated locations in live view. All training, validation, and testing 
was done at the default setting. 
 
2.3 Creating ML modules using Google Cloud AutoML Vision beta 
 
Google cloud AutoML is a suite of machine learning products including AutoML Vision, 
AutoML Natural Language and AutoML Translation[14]. All Cloud Auto ML machine learning 
products are currently in beta version. We used Cloud AutoML Vision beta to create machine 
learning modules for our project. 
As opposed to the Apple Create ML which can be run on a local Apple computer, the Google 
Cloud Auto ML must be run in the cloud. The first step is to create a Google Cloud account. 
Although Google Cloud is a paid service, the first 12 months are offered as a free service with a 
$300 credit.  
For each machine model, we used the following procedure. The main home screen for Google 
Cloud Platform is the console. The option for AutoML is on the upper left-hand side. Choosing 
the “Vision” option, leads to the welcoming screen and presented with a button labeled “get 
started with Vision.” This option leads to the AutoML Vision beta Datasets screen. To create a 
new dataset, one has to choose “New Dataset” button located to the right of “AutoML Vision 
beta” button that is located in the upper left-hand corner of the screen. One then names the data 
set and chooses how to import images. We chose to import images later in order to be able to 
take advantage of the graphical user interface. We left classification type box unchecked because 
each of our image classes had only a single label. Next, we created class labels and imported 
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images for each of the classes to the cloud. The following step involved training a new model. 
This step took on average 8 to 9 minutes. Once completed we received an email notification and 
we could evaluate our trained model. The following information was available: average precision 
(area under the precision-recall tradeoff curve), overall precision and recall, score threshold 
slider, precision-recall graphs, and confusion matrix. Confusion matrix table displays how often 
trained model classifies each label correctly and how often incorrectly (“confused model”). 
 
2.4 Experiment 1  
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to detect and subclassify non-small 
cell lung cancer based on the histopathological images.  
Apple Create ML Image Classifier:  
We created three classes of images (250 images each) with the following labels: Lung_Normal 
(benign lung tissue), Lung_AdenoCA (lung adenocarcinoma), and Lung_SqCA (lung squamous 
cell carcinoma). 80% of the images were randomly assigned to the training folder and 20% to the 
testing folder. The training folder included three class labeled subfolders with training images 
(80% of total). The testing folder included three class labeled subfolders with testing images 
(20% of total). Apple program randomly assigned 5% of images from training folder for 
validation. 
Google Auto ML Vision beta: 
We created three classes of images (250 images each) with the following labels: Lung_Normal 
(benign lung tissue), Lung_AdenoCA (lung adenocarcinoma), and Lung_SqCA (lung squamous 
cell carcinoma). 250 images per class (750 total images) were uploaded to Google Cloud. Google 
AutoML Vision beta randomly assigned 80% for training, 10% for validation, and 10% for 
testing the module. 
 
2.5 Experiment 2  
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to differentiate between normal lung 
tissue and non-small cell lung cancer histopathologic images with 50/50 mixture of lung 
adenocarcinoma and lung squamous cell carcinoma.  
Apple Create ML Image Classifier: 
We created two classes of images (250 images each) with the following labels: Lung Normal 
(benign lung tissue) and Lung NSCLC (non-small cell lung cancer). 80% of the images were 
randomly assigned to the training folder and 20% to the testing folder. The training folder 
included two class labeled subfolders with training images (80% of total). The testing folder 
included two class labeled subfolders with testing images (20% of total). Apple program 
randomly assigned 5% of images from training folder for validation. 
Google Auto ML Vision beta: 
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We created two classes of images (250 images each) with the following labels: Lung_Normal 
(benign lung tissue) and Lung NSCLC (non-small cell lung cancer). 250 images per class (500 
total images) were uploaded to Google Cloud. Google AutoML Vision beta randomly assigned 
80% for training, 10% for validation, and 10% for testing the module. 
 
2.6 Experiment 3  
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to differentiate between lung 
adenocarcinoma and lung squamous cell carcinoma histopathologic images.  
Apple Create ML Image Classifier: 
We created two classes of images (250 images each) with the following labels: Lung AdenoCA 
(adenocarcinoma) and Lung SqCA (squamous cell carcinoma). 80% of the images were 
randomly assigned to the training folder and 20% to the testing folder. The training folder 
included two class labeled subfolders with training images (80% of total). The testing folder 
included two class labeled subfolders with testing images (20% of total).  
Google Auto ML Vision beta: 
We created two classes of images (250 images each) with the following labels: AdenoCA (lung 
adenocarcinoma) and SqCA (lung squamous cell carcinoma). 250 images per class (500 total 
images) were uploaded to Google Cloud. Google AutoML Vision beta randomly assigned 80% 
for training, 10% for validation, and 10% for testing the module. 
 
2.7 Experiment 4 
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to detect colon cancer 
histopathological images regardless of KRAS mutation status.  
Apple Create ML Image Classifier: 
We created two classes of images (250 images each) with the following labels: Colon_Normal 
(benign colon tissue) and Colon_AdenoCA (colon adenocarcinoma). 80% of the images were 
randomly assigned to the training folder and 20% to the testing folder. The training folder 
included two class labeled subfolders with training images (80% of total). The testing folder 
included two class labeled subfolders with testing images (20% of total). Apple program 
randomly assigned 5% of images from training folder for validation. 
Google Auto ML Vision beta: 
We created two classes of images (250 images each) with the following labels: Colon_Normal 
(benign colon tissue) and Colon_AdenoCA (colon adenocarcinoma). 250 images per class (500 
total images) were uploaded to Google Cloud. Google AutoML Vision beta randomly assigned 
80% for training, 10% for validation, and 10% for testing the module. 
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2.8 Experiment 5  
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to differentiate between KRAS 
mutation-positive colon adenocarcinoma and KRAS mutation-negative colon adenocarcinoma 
histopathologic images.  
Apple Create ML Image Classifier: 
We created two classes of images (125 images each) with the following labels: 
KRAS_POS_AdenoCA (colon adenocarcinoma cases with KRAS mutation) and 
KRAS_NEG_AdenoCA (colon adenocarcinoma cases without KRAS mutation). 80% of the 
images were randomly assigned to the training folder and 20% to the testing folder. The training 
folder included two class labeled subfolders with training images (80% of total). The testing 
folder included two class labeled subfolders with testing images (20% of total). Apple program 
randomly assigned 5% of images from training folder for validation. 
Google Auto ML Vision beta: 
We created two classes of images (125 images each) with the following labels: 
AdenoCA_KRAS_Neg (colon adenocarcinoma cases without KRAS mutations) and 
AdenoCA_KRAS_Pos (colon adenocarcinoma cases with KRAS mutations). 125 images per 
class (250 total images) were uploaded to Google Cloud. Google AutoML Vision beta randomly 
assigned 80% for training, 10% for validation, and 10% for testing the module. 
 
2.9 Experiment 6  
 
In this experiment, we compared two machine learning algorithms, Apple Create ML Image 
Classifier and Google Auto ML Vision beta, in their ability to differentiate between lung 
adenocarcinoma and colon adenocarcinoma histopathologic images.  
Apple Create ML Image Classifier: 
We created two classes of images (250 images each) with the following labels: Colon_AdenoCA 
(colon adenocarcinoma) and Lung_AdenoCA (lung adenocarcinoma). 80% of the images were 
randomly assigned to the training folder and 20% to the testing folder. The training folder 
included two class labeled subfolders with training images (80% of total). The testing folder 
included two class labeled subfolders with testing images (20% of total). Apple program 
randomly assigned 5% of images from training folder for validation. 
Google Auto ML Vision beta: 
We created two classes of images (250 images each) with the following labels: AdenoCA_Lung 
(lung adenocarcinoma) and AdenoCA_Colon (colon adenocarcinoma). 250 images per class 
(500 total images) were uploaded to Google Cloud. Google AutoML Vision beta randomly 
assigned 80% for training, 10% for validation, and 10% for testing the module. 
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3. RESULTS 
 
Twelve machine learning models were created in six experiments using the Apple Create ML 
and the Google Auto ML beta. Results of models’ performances in terms of recall and precision 
data are summarized in Table 1. To investigate recall and precision differences between the 
Apple and the Google machine learning algorithms, we performed two-tailed distribution, paired 
t-tests. No statistically significant differences were found (p-value of 0.52 for recall and 0.60 for 
precision). 
Overall, all of the models performed well in distinguishing between normal and neoplastic tissue 
for both lung and colon cancers. In subclassifying non-small cell lung cancer into 
adenocarcinoma and squamous cell carcinoma, the models were shown to have high levels of 
precision and recall. The models were also successful in distinguishing between lung and colonic 
origin of adenocarcinoma (Figures 1-4). However, both Apple Create ML Image Classifier and 
Google Auto ML Vision beta had trouble discerning colon adenocarcinoma with KRAS 
mutations from adenocarcinoma without KRAS mutations.  
 
 
 Table 1. Results summary for the Apple Create ML and the Google Auto ML beta. 
 
 
ML 
Model Classes 
Apple 
Recall 
Google 
Recall 
Apple 
Precision 
Google 
Precision 
  Lung Normal 100.00% 100.00% 98.04% 100.00% 
  Lung AdenoCA 86.00% 85.70% 97.73% 81.80% 
Model 1 Lung SqCA 98.00% 89.90% 89.09% 90.60% 
  Lung Normal 100.00% 100.00% 98.04% 100.00% 
Model 2 NSCLC 98.00% 100.00% 100.00% 100.00% 
  Lung AdenoCA 90.00% 82.40% 91.84% 87.50% 
Model 3 Lung SqCA 92.00% 92.30% 90.20% 88.90% 
  Colon Normal 98.00% 95.80% 100.00% 100.00% 
Model 4 Colon AdenoCA 100.00% 100.00% 98.04% 96.00% 
  Colon AdenoCA KRAS+ 72.00% 88.20% 69.23% 71.40% 
Model 5 Colon AdenoCA KRAS- 68.00% 50.00% 70.83% 75.00% 
  Lung AdenoCA 96.00% 91.30% 96.00% 100.00% 
Model 6 Colon AdenoCA 96.00% 100.00% 96.00% 93.90% 
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4. DISCUSSION 
 
Image classifier models utilizing algorithms via machine learning hold a promising future to 
revolutionize the healthcare field. Machine learning products, such as those modules offered by 
Apple and Google, are easy to use and have a simple graphical user interface to allow individuals 
to train models to perform human-like tasks in real time. In our experiments, we compared 
multiple algorithms to determine their ability to differentiate and subclassify histopathologic 
images with high precision and recall. To compare and contrast these modules, we focused our 
experiments on tasks that highlighted common and characteristic practices of histopathologic 
diagnosis and neoplasm classification.  
 
Through six different experiments crafted to train, validate, and test different machine learning 
products, we examined the performance characteristics and features currently available. Analysis 
of the results revealed high precision and recall values illustrating the models’ ability to 
differentiate and detect benign lung tissue from lung squamous cell carcinoma and lung 
adenocarcinoma in ML model one, benign lung from non-small cell lung carcinoma in ML 
model two, and benign colon from colonic adenocarcinoma in ML model 4. In ML model three 
and six, both machine learning algorithms performed at a high level to differentiate lung 
squamous cell carcinoma from lung adenocarcinoma and lung adenocarcinoma from colonic 
adenocarcinoma, respectively. Of note, ML model 5 had the lowest precision and recall values 
across both algorithms demonstrating the models’ limited utility in predicting molecular profiles 
such as KRAS mutations as tested here. This is not surprising as pathologists currently require 
complex molecular tests to detect KRAS mutations reliably in colon cancer.  
 
Both modules require minimal programming experience and are easy to use. In our comparison 
we demonstrate critical distinguishing characteristics that differentiate the two products.  
 
Apple CreateML image classifier is available for use on local Mac computers that use Xcode 
version 10 and macOS 10.14, with just three lines of code required to perform computations. 
While this product is limited to Apple products, it is free to use and images are stored on the 
computer hard drive. Of unique significance, on the Apple system platform images can be 
augmented to alter the appearance to enhance model training. For example, imported images can 
be cropped, rotated, blurred, and flipped, in order to optimize the model’s training abilities to 
recognize test images and perform pattern recognition. This feature is not available on the 
Google module. Apple CreateML Image classifier’s default training set consists of 75% of total 
imported images with 5% of the total images being randomly utilized as a validation set. The 
remaining 20% of images comprise the testing set. The module’s computational analysis to train 
the model is achieved in approximately 2 minutes on average. The score threshold is set at 50% 
and cannot be manipulated for each image class as in Google AutoML Vision beta. 
 
Google AutoML Vision beta is open to many platforms and stores images on the Google Cloud, 
but it is important to note that it requires computing fees. Google gives new users 12 months of 
service for free with $300 for spending prior to charges required for model training functions. On 
AutoML Vision beta, random 80% of the total images are used in the training set, 10% are used 
in the validation set, and 10% are used in the testing set. It is important to highlight the different 
percentages used in the default settings on the respective modules. The time to train the Google 
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AutoML Vision beta with default computational power is longer on average than Apple 
CreateML, with approximately 8 minutes required to train the machine learning module. It is, 
however, possible to choose more computational power for an additional fee and decrease 
module training time. The user will receive an email when the computer time begins and an 
email when the computing is completed. This allows users to perform other tasks and return 
when the training is complete, at which time the user is notified via email. The computation time 
is calculated by subtracting the time of the initial email from the final email.  
 
Based on our calculations we determined there was no significant difference between the two 
machine learning algorithms tested at the default settings with recall and precision values 
obtained. These findings demonstrate the promise of using a machine learning algorithm to assist 
in the performance of human tasks and behaviors, specifically the diagnosis of histopathologic 
images. These results have numerous potential uses in clinical medicine. Machine learning 
algorithms have been successfully applied to diagnostic and prognostic endeavors in 
pathology[23]–[28], dermatology[29]–[31], ophthalmology[32], cardiology[33], and 
radiology[34]–[36]. Pathologists often employ additional tests, such as special staining of tissues 
or molecular tests, to assist with accurate classification of tumors. Machine learning platforms 
offer the potential of an additional tool for Pathologists to utilize along with human microscopic 
interpretation[37][38]. In addition, many countries have marked physician shortages, especially 
in fields of specialized training such as pathology[39]–[41]. These models could readily assist 
physicians in these countries to treat patients with more specific diagnoses provided in a timely 
manner[42]. Finally, while we have explored the application of these platforms in common 
cancer scenarios, there is great potential to use similar techniques in the detection of other 
conditions. These include the potential for classification and risk assessment of precancerous 
lesions, infectious processes in tissue (e.g., detection of tuberculosis or malaria)[24][43], 
inflammatory conditions (e.g., arthritis subtypes, gout,)[44], blood disorders (e.g., abnormal 
blood cell morphology)[45] and many others. The potential of these technologies appears to be 
limited only by the imagination of the user[46]. 
 
Regarding the limited effectiveness in determining the presence or absence of KRAS mutations 
in colon adenocarcinoma, it is mentioned that currently, pathologists rely on complex molecular 
tests to detect the mutations at the DNA level[21]. It is possible that the use of more extensive 
training data sets may improve recall and precision in cases such as these and warrants further 
study. Our experiments were limited to the stipulations placed by the free trial software 
agreements; no costs were expended to utilize the algorithms, though an Apple computer was 
required. 
 
5. CONCLUSIONS 
 
In summary, Google Cloud Auto ML and Apple Create ML are democratizing machine learning. 
In our trained models for lung and colon cancer diagnosis, they both performed very well 
individually, and no statistically significant differences were found between the two platforms. 
However, there are some critical factors that set them apart. Apple Create ML can be used on 
local computers but is limited to an Apple ecosystem. Google Auto ML is not platform specific 
but runs only in Google Cloud with associated computational fees. In the end, both are excellent 
machine learning tools that have great potential in the field of diagnostic pathology, and which 
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one to choose would depend on personal preference, programming experience, and available 
storage space. 
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Figure 1.  Screenshot of results using Google AutoML to differentiate lung adenocarcinoma from colon adenocarcinoma. 
Overall precision and recall data (Experiment 6). 
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Figure 2.  Screenshot of results using Google AutoML to differentiate lung adenocarcinoma from colon adenocarcinoma. 
Precision and recall data for lung adenocarcinoma label (Experiment 6). 
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Figure 3.  Screenshot of results using Google AutoML to differentiate lung adenocarcinoma from colon adenocarcinoma. 
Precision and recall data for colon adenocarcinoma label (Experiment 6). 
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Figure 4.  Screenshot of results using Apple Create ML demonstrating precision and recall differentiating lung adenocarcinomas from 
colon adenocarcinoma.  Users can scroll through all images in the field on the right to review results for individual images 
(Experiment 6). 
